BSX
Boston Scientific Corporation · Healthcare · Medical - Devices
Momentum-inputs (vergelijkbare managers):
breedte van houders -3.7% ·
aandelenstroom +0.1% ·
netto nieuwe posities -3.8%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 7.31M | $317.13M | n/a | n/a |
| Q2 2026 | 180 | -1 | 1.05B | $45.33B | +3 | −5 |
| Q1 2026 | 185 | -2 | 1.08B | $67.75B | +2 | −5 |
| Q4 2025 | 186 | +1 | 1.13B | $107.60B | +2 | n/a |
| Q3 2025 | 28 | 0 | 719.46M | $70.18B | n/a | −1 |
| Q2 2025 | 26 | -1 | 668.30M | $71.71B | n/a | −1 |
| Q1 2025 | 24 | +1 | 275.71M | $27.75B | +1 | n/a |
| Q4 2024 | 23 | -1 | 268.54M | $23.93B | n/a | −1 |
| Q3 2024 | 23 | +2 | 200.54M | $16.75B | +2 | n/a |
| Q2 2024 | 21 | n/a | 195.84M | $15.04B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 146.69M | n/a | $15.76B | 0.3% | n/c | 1 | SEC ↗ ×22 |
| 2 | The Vanguard Group ✦ (passief) | 137.13M | n/a | $14.73B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 3 | Fidelity (FMR) ✦ | 108.31M | n/a | $11.63B | 0.7% | n/c | 1 | SEC ↗ ×7 |
| 4 | State Street Global Advisors ✦ (passief) | 65.19M | +1.1% | $7.00B | 0.3% | ▲ Add | 3 | SEC ↗ |
| 5 | PRIMECAP Management ✦ | 34.66M | -5.0% | $3.72B | 3.0% | ▼ Trim | 5 | SEC ↗ |
| 6 | Wellington Management ✦ | 32.65M | -1.6% | $3.51B | 0.6% | ▼ Trim | 5 | SEC ↗ ×9 |
| 7 | Geode Capital Management ✦ (passief) | 32.42M | +2.0% | $3.47B | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Capital World Investors ✦ | 28.52M | -0.1% | $3.06B | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (passief) | 19.46M | -2.6% | $2.09B | 0.3% | ▼ Trim | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 11.02M | +3.9% | $1.18B | 0.1% | ▲ Add | 5 | SEC ↗ ×2 |
| 11 | Fisher Asset Management ✦ | 7.71M | +13.9% | $827.64M | 0.3% | ▲ Add | 5 | SEC ↗ |
| 12 | Marshall Wace ✦ | 7.50M | -5.7% | $805.32M | 1.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 13 | D. E. Shaw & Co. ✦ | 6.76M | +76.0% | $725.57M | 0.8% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Arrowstreet Capital ✦ | 6.53M | -3.3% | $701.38M | 0.5% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 5.40M | -0.5% | $580.48M | 0.5% | ▼ Trim | 5 | SEC ↗ ×2 |
| 16 | Millennium Management ✦ | 4.64M | -44.4% | $444.25M | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 17 | Viking Global Investors ✦ | 3.05M | +28.1% | $327.15M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 2.47M | +1.1% | $264.91M | 0.5% | ▲ Add | 5 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 2.46M | +30.9% | $264.30M | 0.7% | ▲ Add | 5 | SEC ↗ |
| 20 | Adage Capital Partners ✦ | 2.06M | -20.7% | $220.77M | 0.4% | ▼ Trim | 5 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 1.84M | +59.5% | $197.11M | 0.2% | ▲ Add | 5 | SEC ↗ ×7 |
| 22 | Renaissance Technologies ✦ | 1.50M | +129.7% | $160.74M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 125.20K | -1.1% | $13.45M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 24 | Dodge & Cox ✦ | 90.39K | -1.4% | $9.71M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 74.52K | +113.1% | $8.00M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 26 | Bridgewater Associates ✦ | 48.28K | -24.5% | $5.19M | 0.0% | ▼ Trim | 5 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Soros Fund Management | $10.09M | was 0.3% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1,653 houders, 1.31B aandelen, $78.98B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Director · 2.04K aand @ 49.22 · $100,408
Open-market verkopen (S)
Geen open-market insider-verkopen in ons dekkingsvenster.
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie